Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ameriprise Financial Inc.

Key Points

• Ameriprise Financial Inc. increased its holdings in Regeneron Pharmaceuticals by 4.2% in the first quarter, owning 340,145 shares valued at approximately $215.57 million.
• Regeneron reported earnings of $12.89 per share, exceeding estimates by $4.46, with revenue of $3.68 billion for the quarter, up 3.6% year-over-year.
• The company announced a quarterly dividend of $0.88 per share, resulting in an annual yield of 0.6% for shareholders of record.

Ameriprise Financial Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 340,145 shares of the biopharmaceutical company's stock after buying an additional 13,594 shares during the period. Ameriprise Financial Inc. owned approximately 0.31% of Regeneron Pharmaceuticals worth $215,571,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Norinchukin Bank The boosted its position in shares of Regeneron Pharmaceuticals by 44.2% during the first quarter. Norinchukin Bank The now owns 8,378 shares of the biopharmaceutical company's stock worth $5,314,000 after buying an additional 2,568 shares during the period. CW Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $920,000. Summit Financial LLC raised its holdings in Regeneron Pharmaceuticals by 0.6% during the first quarter. Summit Financial LLC now owns 10,596 shares of the biopharmaceutical company's stock worth $6,720,000 after purchasing an additional 64 shares in the last quarter. Kaufman Rossin Wealth LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $218,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $589.48 on Friday. The stock has a market capitalization of $62.48 billion, a P/E ratio of 14.86, a P/E/G ratio of 1.99 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The business's fifty day moving average is $550.48 and its two-hundred day moving average is $592.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.56 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Citigroup reissued a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Robert W. Baird dropped their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Finally, The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.